Lilly trades at a premium to Ozempic-maker Novo as obesity drugs boom
Does Eli Lilly should trade at a premium to Novo Nordisk shares? For Deutsche Bank analyst James Shin, the reply ...
Does Eli Lilly should trade at a premium to Novo Nordisk shares? For Deutsche Bank analyst James Shin, the reply ...